期刊文献+

RELATIONSHIP BETWEEN THE CLINICAL USE OF ANTIBIOTIC AND PRODUCTION OF ESBLS

RELATIONSHIP BETWEEN THE CLINICAL USE OF ANTIBIOTIC AND PRODUCTION OF ESBLS
下载PDF
导出
摘要 Objective:To determine the relationship between the application of antibiotic and the production of extended spectrum β-lactamases (ESBLs).Methods:ESBLs were detected by the double disc diffusion method among 161 gram-negative bacilli isolated from clinical specimens.The use of antibiotic in the patients was investigated before ESBLs were detected. Results:The rate of ESBLs-producing strains was 35.4% (57/161). In the patients with ESBLs-producing strains, the utilization rates of antibiotic and the third-generation cephalosprin were 96.4% (55/57) and 42.1% (24/57) respectively, which were significantly higher than those without ESBLs-producing strains [80.6% (84/104) and 16.3% (17/104), respectively].There were significant differences ( P <0.05 and P <0.005,respectively) between the two groups of patients.The duration of the third-generation cephalosprins therapy was significantly longer in the patients with ESBLs-producing strains [(7.5 ± 5.4)d] than those without ESBLs-producing strains [(2.7±2.6)d, P <0.05].Conclusion:The application of antibiotic, especially the third-generation cephalosprins, is the risk factor for the production of ESBLs. Objective:To determine the relationship between the application of antibiotic and the production of extended spectrum β-lactamases (ESBLs).Methods:ESBLs were detected by the double disc diffusion method among 161 gram-negative bacilli isolated from clinical specimens.The use of antibiotic in the patients was investigated before ESBLs were detected. Results:The rate of ESBLs-producing strains was 35.4% (57/161). In the patients with ESBLs-producing strains, the utilization rates of antibiotic and the third-generation cephalosprin were 96.4% (55/57) and 42.1% (24/57) respectively, which were significantly higher than those without ESBLs-producing strains [80.6% (84/104) and 16.3% (17/104), respectively].There were significant differences ( P <0.05 and P <0.005,respectively) between the two groups of patients.The duration of the third-generation cephalosprins therapy was significantly longer in the patients with ESBLs-producing strains [(7.5 ± 5.4)d] than those without ESBLs-producing strains [(2.7±2.6)d, P <0.05].Conclusion:The application of antibiotic, especially the third-generation cephalosprins, is the risk factor for the production of ESBLs.
出处 《中国现代医学杂志》 CAS CSCD 2003年第8期18-20,共3页 China Journal of Modern Medicine
基金 ThisworkwassupportedbygrantsfromtheWeiShengTingofHunanProvince (NO .0 0 0 3 0 )
关键词 抗生素 ESBLS 细菌 临床应用 Extended Spectrum β-lactamases Antibiotic Bacteria
  • 相关文献

参考文献7

  • 1XL. Mu, LX He, ZY Zhou, et al. Detection and Typing of ESBLs and drug Susceptibility of ESBLs - producing bacteria. J of China antibiotic,2000; 25:194~ 196.
  • 2George A. Epidemiology of Extended - spectrun β- Lactamase.Clin. Infection Disease, 1998;27:81 ~83.
  • 3Maki DG. Risk for nosocomial infection in intensive care. Arch intern Met], 1989; 149:30--37.
  • 4Lautenbach E, Patal JB, Bilker WB, et al. ESBLs - producing Escherichia coil and Klehsiella pneumoniae factor for infection and impact of resistance on outcomes. Clin. infection Disease, 2001 ; 32:1162~ 1171.
  • 5Emery C. L., Weymouth L.A. Detection and clinical significance of extended - spectrum β - lactamase in Atertiary - Care Medical Center. J. Clin Micro, 1997;35:2061 ~2067.
  • 6Mayer KS, Ubran C, Eagan JA, et al. Nosocomial outbreaks of Klebsiella infection - resistant to third - generation cepholosporin.Ann Intern Med, 1993; 119: 353 -- 358.
  • 7Naumovski L, Quinn GP, Miyasshim D, et al. Outbreak of ceftazidime resistance due to novel ESBLs in isolates from cancer patients. Antimicrob. Agents. Chember, 1992;36:1991 -- 1996.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部